Information Provided By: 
Fly News Breaks for April 29, 2019
IOVA
Apr 29, 2019 | 05:10 EDT
Piper Jaffray analyst Joseph Catanzaro started Iovance Biotherapeutics with an Overweight rating and $20 price target. The company has "clearly demonstrated the ability to produce a cell therapy with consistent and impressive efficacy in multiple solid tumor settings," Catanzaro tells investors in a research note. He believes response rates of 30%-40% position Iovance for multiple potential approvals over the next five years that include melanoma, cervical cancer, and head and neck cancer.
News For IOVA From the Last 2 Days
There are no results for your query IOVA
